A Phase I Study of Bevacizumab (B) in Combination with Everolimus (E) and Erlotinib (E) in Advanced Cancer (BEE)

PURPOSE: VEGF, mTOR, and EGFR inhibitors have demonstrated anti-tumor and anti-angiogenic effects alone and in combination with each other. This study evaluated the safety, tolerability, and pharmacokinetics of bevacizumab, everolimus and erlotinib combination. METHODS: Doublet therapy consisted of...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Bullock, Karen E., Petros, William P., Younis, Islam, Uronis, Hope E., Morse, Michael A., Blobe, Gerard C., Zafar, S. Yousuf, Gockerman, Jon P., Lager, Joanne J., Truax, Roxanne, Meadows, Kellen L., Howard, Leigh A., O’Neill, Margot M., Broadwater, Gloria, Hurwitz, Herbert I., Bendell, Johanna C.
Formato: Artigo
Idioma:Inglês
Publicado em: 2010
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC4086252/
https://ncbi.nlm.nih.gov/pubmed/21079958
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s00280-010-1507-6
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados